CN106491601A - A kind of Amino Acid Compound Injection and preparation method thereof - Google Patents
A kind of Amino Acid Compound Injection and preparation method thereof Download PDFInfo
- Publication number
- CN106491601A CN106491601A CN201610936010.5A CN201610936010A CN106491601A CN 106491601 A CN106491601 A CN 106491601A CN 201610936010 A CN201610936010 A CN 201610936010A CN 106491601 A CN106491601 A CN 106491601A
- Authority
- CN
- China
- Prior art keywords
- injection
- amino acid
- water
- acid compound
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 55
- 239000007924 injection Substances 0.000 title claims abstract description 55
- -1 Amino Acid Compound Chemical class 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 229940024606 amino acid Drugs 0.000 claims abstract description 39
- 235000001014 amino acid Nutrition 0.000 claims abstract description 39
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 24
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 17
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003136 leucine Drugs 0.000 claims abstract description 13
- 229960004295 valine Drugs 0.000 claims abstract description 13
- 239000004475 Arginine Substances 0.000 claims abstract description 12
- 239000004471 Glycine Substances 0.000 claims abstract description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004473 Threonine Substances 0.000 claims abstract description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 12
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 12
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000018417 cysteine Nutrition 0.000 claims abstract description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960000310 isoleucine Drugs 0.000 claims abstract description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000008729 phenylalanine Nutrition 0.000 claims abstract description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 11
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000004279 alanine Nutrition 0.000 claims abstract description 11
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 11
- 239000004220 glutamic acid Substances 0.000 claims abstract description 11
- 229930182817 methionine Natural products 0.000 claims abstract description 11
- 229960004441 tyrosine Drugs 0.000 claims abstract description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000008215 water for injection Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 235000006708 antioxidants Nutrition 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 235000013930 proline Nutrition 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- NSENZNPLAVRFMJ-UHFFFAOYSA-N 2,3-dibutylphenol Chemical compound CCCCC1=CC=CC(O)=C1CCCC NSENZNPLAVRFMJ-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 1
- 235000004515 gallic acid Nutrition 0.000 claims 1
- 229940074391 gallic acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 239000013589 supplement Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 3
- 230000002045 lasting effect Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000036449 good health Effects 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000005550 amino acid supplement Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000005687 corn oil Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000012528 membrane Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- AQGDXJQRVOCUQX-UHFFFAOYSA-N N.[S] Chemical compound N.[S] AQGDXJQRVOCUQX-UHFFFAOYSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of Amino Acid Compound Injection and preparation method thereof, contains following solute in every 1000mL injection：9 ~ 12g of isoleucine, 12.5 ~ 15g of Leucine, 9 ~ 10.5g of L-Lysine Acetate, 4 ~ 4.5g of methionine, 6.5 ~ 7g of phenylalanine, 7 ~ 7.5g of threonine, 1 ~ 1.3g of tryptophan, 14 ~ 16g of L-Valine, 6.5 ~ 7.5g of alanine, 9 ~ 10g of arginine, 0.8 ~ 1g of Aspartic Acid, 0.3 ~ 0.8g of glutamic acid, 4.5 ~ 5g of histidine, proline-4 .5 ~ 5g, 1.5 ~ 1.8g of serine, 0.4 ~ 0.6g of L-Tyrosine, 6.5 ~ 7g of glycine, 0.01 ~ 0.3g of 0.3 ~ 0.5g of cysteine and antioxidant.Improve supplement, the assimilation effect of aminoacid, user is allowed to keep vigorous energy, save time and the medicine irritation of a large amount of injections, substantially improve the deficiency of existing amino acid injection, have the advantages that formula reasonable, efficacy lasting, absorption of human body is good, good health care effect.
Description
Technical field
The invention belongs to injection field, is related to a kind of amino acid injection, and in particular to a kind of amino acid injection
Liquid and preparation method thereof.
Background technology
The elementary cell of protein structure is aminoacid.Human body needs to take in a certain amount of protein to meet life daily
The needs of activity, when taking in q.s from gastrointestinal tract because of certain reason, just must be input into Freamine Ⅲ by vein
Supplement is given, Amino Acid Compound Injection (18AA) is very important amino acid supplements and therapeutic agent, clinically plays
Important effect.The mixture of these three aminoacid composition of the Leucine, isoleucine, L-Valine in essential amino acids, scientific name
Be branched-chain amino acid, it is a kind of particularly significant and effective nutritional supplement, it can help organism naturally, there is no secondary work
Enhancing muscle obtains more multi-energy, alleviates muscle fatigue, strengthens muscle strength, fast quick-recovery after being particularly suited for motion
Muscle power and supplement the nutrients when improving body protein Developmental and Metabolic Disorder, patient etc..
If human body intake aminoacid is not enough, need to be supplemented using amino acid supplements.Common amino acid supplements
It is divided into oral and two kinds of injection, Moriamin Forte tonic is easy to carry, and can take at any time, but Moriamin Forte tonic is to pass through
Digestive system is absorbed, and the amino on aminoacid can be sloughed by the transaminase in liver, most amino acid converting for Fructus Vitis viniferae at last
Sugar, availability are low, and tonic effect can be substantially reduced.Injection amino acid supplements are directly to note amino acid injection by vein
Penetrate, aminoacid is dissolved in body fluid, directly absorbed by muscle or its hetero-organization, instant effect, but during injection amino acid supplements, people's
Activity can be restricted, fast due to absorbing, and need often to carry out injection intake, can take a substantial amount of time.
Content of the invention
The invention aims to overcoming the deficiencies in the prior art and providing a kind of improvement existing injection amino acid supplements
Absorb the slow, Amino Acid Compound Injection of transfusion time length.
For reaching above-mentioned purpose, the technical solution adopted in the present invention is：A kind of Amino Acid Compound Injection, per 1000mL
Contain following solute in injection：9～12g of isoleucine, 12.5～15g of Leucine, 9～10.5g of L-Lysine Acetate, first sulfur ammonia
4～4.5g of acid, 6.5～7g of phenylalanine, 7～7.5g of threonine, 1～1.3g of tryptophan, 14～16g of L-Valine, alanine 6.5
～7.5g, 9～10g of arginine, 0.8～1g of Aspartic Acid, 0.3～0.8g of glutamic acid, 4.5～5g of histidine, proline-4 .5～
5g, 1.5～1.8g of serine, 0.4～0.6g of L-Tyrosine, 6.5～7g of glycine, 0.3～0.5g of cysteine and antioxidant
0.01～0.3g.
Optimally, the antioxidant is sodium sulfite, sodium pyrosulfite, dibutylphenol, sodium thiosulfate, the tert-butyl group
P-hydroxyanisole, thiourea, vitamin C, propylgallate, alpha-tocopherol or ascorbyl palmitate.
A further object of the present invention is to provide a kind of preparation method of above-mentioned Amino Acid Compound Injection, and it includes following
Step：
(a) wash bottle：Infusion bottle is rinsed with aqueous alkali, drinking water, purified water and water for injection respectively, is subsequently sent
To bottling department；
B () matches somebody with somebody liquid：Antioxidant is dissolved in formation antioxidant solution in water for injection first, 50～70 DEG C are heated to, to
Wherein being passed through nitrogen makes which contain dissolved oxygen less than 0.5ppm, under conditions of continuous nitrogen charging and stirring, adds arginine stirring
Dissolving, is subsequently sequentially added into serine, glutamic acid, glycine, L-Valine, phenylalanine, alanine, Aspartic Acid, dried meat ammonia
Acid, L-Tyrosine, isoleucine, Leucine, histidine, threonine and methionine stirring and dissolving；25～45 DEG C are cooled to, are being stirred
Cysteine, L-Lysine Acetate and tryptophan is sequentially added under the conditions of mixing, and mends water for injection to full dose；
C mixed liquor that step (b) is obtained by () is injected in the infusion bottle, is controlled remaining oxygen control in which and is less than
2.0%, sterilize after rolling lid sealing.
Optimally, in step (a), containing the NaOH that mass concentration is 1～2% in the aqueous alkali, its temperature is 45～55
℃；The water for injection temperature is maintained at more than 70 DEG C；Flushing pressure is not less than 0.15MPa.
Optimally, in step (b), mend water for injection be added thereto to account for full dose its mass fraction for 0.02～
0.1% needle-use activated carbon, stirs and controls its pH for 6.8～7.8.
As above-mentioned technical proposal is used, the present invention has following advantages compared with prior art：Compound amino of the present invention
Acid injection, by the nutritional labeling and functional component of rational proportion, plays the synergism of each component to greatest extent, improves
The supplement of aminoacid, assimilation effect, allow user to keep vigorous energy, save time and the medicine irritation of a large amount of injections,
Substantially improve the deficiency of existing amino acid injection, with formula reasonable, efficacy lasting, absorption of human body is good, good health care effect
Advantage.
Specific embodiment
The preferred embodiment of the invention will be described in detail below.
Embodiment 1
The present embodiment provides a kind of Amino Acid Compound Injection, contains following solute in every 1000mL injection：Different bright ammonia
Sour 9.1g, Leucine 12.9g, L-Lysine Acetate 10g, methionine 4.4g, phenylalanine 7g, threonine 7.5g, tryptophan
1.3g, L-Valine 14g, alanine 7.1g, arginine 9g, Aspartic Acid 1g, glutamic acid 0.5g, histidine 5g, proline 5g, silk
Propylhomoserin 1.7g, L-Tyrosine 0.4g, glycine 7g, cysteine 0.35g and sodium sulfite 0.3g, appropriate water for injection；
The preparation method of above-mentioned Amino Acid Compound Injection, it comprises the following steps：
(a) wash bottle：Respectively with aqueous alkali (mass concentration of NaOH be 1～2%), drinking water, purified water and water for injection (on
State and 45～55 DEG C are with water, its pressure is not less than 0.15MPa)；
B () matches somebody with somebody liquid：Antioxidant is dissolved in formation antioxidant solution in water for injection first, 50 DEG C is heated to, thereto
Being passed through nitrogen makes which contain dissolved oxygen less than 0.5ppm, under conditions of continuous nitrogen charging and stirring, adds arginine stirring and dissolving,
Serine, glutamic acid, glycine, L-Valine, phenylalanine, alanine, Aspartic Acid, proline, cheese are subsequently sequentially added into
Propylhomoserin, isoleucine, Leucine, histidine, threonine and methionine stirring and dissolving；25 DEG C are cooled to, under agitation
Cysteine, L-Lysine Acetate and tryptophan is sequentially added, and water for injection is mended to full dose；
C mixed liquor that step (b) is obtained by () is injected in the infusion bottle, is controlled remaining oxygen control in which and is less than
2.0%, sterilize after rolling lid sealing.
Embodiment 2
The present embodiment provides a kind of Amino Acid Compound Injection, basically identical in its formula and embodiment 1, different
It is that step (b) is：Antioxidant is dissolved in formation antioxidant solution in water for injection first, 70 DEG C is heated to, is passed through thereto
Nitrogen makes which contain dissolved oxygen less than 0.5ppm, under conditions of continuous nitrogen charging and stirring, adds arginine stirring and dissolving, subsequently
Be sequentially added into serine, glutamic acid, glycine, L-Valine, phenylalanine, alanine, Aspartic Acid, proline, L-Tyrosine,
Isoleucine, Leucine, histidine, threonine and methionine stirring and dissolving；45 DEG C are cooled to, are added successively under agitation
Enter cysteine, L-Lysine Acetate and tryptophan, water for injection is mended to full dose；It is added thereto to account for its mass fraction for 0.02%
Needle-use activated carbon control its pH and be about 6.8, mend water for injection to full dose；Filter through melt-blown filter, then (aperture is with filter membrane
0.2～0.5 μm) filter.
Embodiment 3
The present embodiment provides a kind of Amino Acid Compound Injection, basically identical in its formula and embodiment 1, different
It is that step (b) is：Antioxidant is dissolved in formation antioxidant solution in water for injection first, 60 DEG C is heated to, is passed through thereto
Nitrogen makes which contain dissolved oxygen less than 0.5ppm, under conditions of continuous nitrogen charging and stirring, adds arginine stirring and dissolving, subsequently
Be sequentially added into serine, glutamic acid, glycine, L-Valine, phenylalanine, alanine, Aspartic Acid, proline, L-Tyrosine,
Isoleucine, Leucine, histidine, threonine and methionine stirring and dissolving；30 DEG C are cooled to, are added successively under agitation
Enter cysteine, L-Lysine Acetate and tryptophan, water for injection is mended to full dose；It is added thereto to account for its mass fraction for 0.1%
Needle-use activated carbon control its pH and be about 7.8, mend water for injection to full dose；Filter through melt-blown filter, then (aperture is with filter membrane
0.2～0.5 μm) filter.
Embodiment 4
The present embodiment provides a kind of Amino Acid Compound Injection, basically identical in its formula and embodiment 1, different
It is that step (b) is：Antioxidant is dissolved in formation antioxidant solution in water for injection first, 65 DEG C is heated to, is passed through thereto
Nitrogen makes which contain dissolved oxygen less than 0.5ppm, under conditions of continuous nitrogen charging and stirring, adds arginine stirring and dissolving, subsequently
Be sequentially added into serine, glutamic acid, glycine, L-Valine, phenylalanine, alanine, Aspartic Acid, proline, L-Tyrosine,
Isoleucine, Leucine, histidine, threonine and methionine stirring and dissolving；35 DEG C are cooled to, are added successively under agitation
Enter cysteine, L-Lysine Acetate and tryptophan, water for injection is mended to full dose；It is added thereto to account for its mass fraction for 0.05%
Needle-use activated carbon control its pH and be about 7.1, mend water for injection to full dose；Filter through melt-blown filter, then (aperture is with filter membrane
0.2～0.5 μm) filter.
Embodiment 5
The present embodiment provides a kind of Amino Acid Compound Injection, basically identical in its formula and embodiment 3, different
It is that its formula is inconsistent with which, specially：Contain following solute in per 1000mL injection：Isoleucine 9g, Leucine 15g,
L-Lysine Acetate 10.5g, methionine 4.5g, phenylalanine 7g, threonine 7.5g, tryptophan 1.3g, L-Valine 16g, the third ammonia
Sour 7.5g, arginine 10g, Aspartic Acid 1g, glutamic acid 0.8g, histidine 5g, proline 5g, serine 1.8g, L-Tyrosine
0.6g, glycine 7g, cysteine 0.5g and sodium pyrosulfite 0.3g.
Embodiment 6
The present embodiment provides a kind of Amino Acid Compound Injection, basically identical in its formula and embodiment 3, different
It is that its formula is inconsistent with which, specially：Contain following solute in per 1000mL injection：Isoleucine 12g, Leucine
12.5g, L-Lysine Acetate 9g, methionine 4g, phenylalanine 6.5g, threonine 7g, tryptophan 1g, L-Valine 14g, alanine
6.5g, arginine 9g, Aspartic Acid 0.8g, glutamic acid 0.3g, histidine 4.5g, proline-4 .5g, serine 1.5g, L-Tyrosine
0.4g, glycine 6.5g, cysteine 0.3g and ascorbyl palmitate 0.01g.
Amino Acid Compound Injection in embodiment 1 to 6 presses the projects such as light transmittance, content of beary metal, bacterial endotoxin
Inspection method, detects, testing result is as shown in table 1 respectively to which.
The test data of obtained Amino Acid Compound Injection in 1 embodiment 1 to 5 of table
White mice 100 is taken, is divided into five groups, 50 per group；Per two weeks, injection once (is respectively adopted embodiment 1 to reality
Apply the Amino Acid Compound Injection in example 6), comparing result is distinguished in paired observation three months：Injection in injection embodiment 6
Mice is dynamic, Coordinating Muscle ability high, and as nimble as a squirrel, chaeta softness is glossy for action, and body weight has apparent increase, always has
Efficiency 96%；In injection embodiment 4 and embodiment 5 injection experimental group mice is dynamic, Coordinating Muscle ability high, action
Agility, chaeta softness is glossy, and body weight is significantly increased, total effective rate 94%；In injection embodiment 3, injection experimental group is little
Mus are dynamic, Coordinating Muscle ability high, physical agility, and chaeta softness is glossy, and body weight has increase, total effective rate 91%；Note
The mice of penetrating injection experimental group in embodiment 2 is dynamic, Coordinating Muscle ability is high, physical agility, and chaeta softness is glossy,
Body weight has increase, total effective rate 91%；In injection embodiment 1, in injection experimental group, mice is active, and Coordinating Muscle ability is high, body
Hair is soft glossy, and body weight has increase, total effective rate 90%.
Nitrogen balance test：Nitrogen balance test is carried out to 20 posthepatitic cirrhosises patients separately, wherein male 10, female 10,
Age 40-65 year, average 50 years old, which pressed standard diagnostics, and Child-Pugh classifications are A levels.The non-protein heat energy for the treatment of group is adopted
With 25% glucose and 10% lipomul, lipomul accounts for the 50% of non-protein heat energy；Nitrogen source is using prepared by embodiment 6 answering
Square amino acid injection, in addition supplements water soluble vitamins, fatsoluble vitamin, trace element and electrolyte；Each case is adopted
Use deep venous puncture.The non-protein heat energy of matched group is also adopted by 25% glucose and 10% lipomul, and lipomul is accounted for
The 50% of non-protein heat energy；Nitrogen source adopts commercially available Amino Acid Compound Injection (18AA), in addition supplements water soluble vitamins, fat
Soluble vitamin, trace element and electrolyte；Each case adopts deep venous puncture.
During whole medication, vital sign (body temperature, heart rate, respiratory frequency, the blood for the treatment of group and matched group patient
Pressure) all within the normal range, two groups is significant difference for change.Treatment group's adverse reaction rate is few, mild degree, and clinical practice is pacified
Good perfection.As a result show that the patient for the treatment of group obtains rapidly positive nitrogen balance, treatment group and matched group have significance difference between 6 days
Different (P ＜ 0.05), correction data is as shown in table 2：
2 nitrogen balance test of table
| Treatment group (mg/kg/day) | Matched group (mg/kg/day) | |
| First day | -8 | -6 |
| Second day | 0 | -4 |
| 3rd day | 5 | 1 |
| 4th day | 15 | 6 |
| 5th day | 20 | 10 |
| 6th day | 26 | 15 |
In sum, regulation Plasma Amine Acid is more beneficial for using Amino Acid Compound Injection of the present invention tend to normal,
The supplement of aminoacid and assimilation effect preferably, promote the lasting supplementary result of aminoacid better than existing commercially available prod, patient's body
Nutriture and immunity have obtained good lifting, are conducive to patient to get well faster, so as to improve curative effect.
Above-described embodiment technology design only to illustrate the invention and feature, its object is to allow person skilled in the art
Scholar will appreciate that present disclosure and implement according to this, can not be limited the scope of the invention with this.All according to the present invention
Equivalence changes or modification that spirit is made, should all be included within the scope of the present invention.
Claims (5)
1. a kind of Amino Acid Compound Injection, it is characterised in that contain following solute in per 1000mL injection：Isoleucine 9
~ 12g, 12.5 ~ 15g of Leucine, 9 ~ 10.5g of L-Lysine Acetate, 4 ~ 4.5g of methionine, 6.5 ~ 7g of phenylalanine, threonine 7 ~
7.5g, 1 ~ 1.3g of tryptophan, 14 ~ 16g of L-Valine, 6.5 ~ 7.5g of alanine, 9 ~ 10g of arginine, 0.8 ~ 1g of Aspartic Acid, paddy ammonia
0.3 ~ 0.8g of acid, 4.5 ~ 5g of histidine, proline-4 .5 ~ 5g, 1.5 ~ 1.8g of serine, 0.4 ~ 0.6g of L-Tyrosine, glycine 6.5 ~
7g, 0.01 ~ 0.3g of 0.3 ~ 0.5g of cysteine and antioxidant.
2. Amino Acid Compound Injection according to claim 1, it is characterised in that：The antioxidant be sodium sulfite,
Sodium pyrosulfite, dibutylphenol, sodium thiosulfate, butylated hydroxyarisol, thiourea, vitamin C, gallic acid third
Ester, alpha-tocopherol or ascorbyl palmitate.
3. the preparation method of Amino Acid Compound Injection described in a kind of claim 1 or 2, it is characterised in that it includes following
Step：
（a）Wash bottle：Infusion bottle is rinsed with aqueous alkali, drinking water, purified water and water for injection respectively, subsequently delivers to filling
Between dress；
（b）Match somebody with somebody liquid：Antioxidant is dissolved in formation antioxidant solution in water for injection first, 50 ~ 70 DEG C is heated to, is led to thereto
Entering nitrogen makes which contain dissolved oxygen less than 0.5ppm, under conditions of continuous nitrogen charging and stirring, adds arginine stirring and dissolving, with
After be sequentially added into serine, glutamic acid, glycine, L-Valine, phenylalanine, alanine, Aspartic Acid, proline, cheese ammonia
Acid, isoleucine, Leucine, histidine, threonine and methionine stirring and dissolving；25 ~ 45 DEG C are cooled to, under agitation
Cysteine, L-Lysine Acetate and tryptophan is sequentially added, and water for injection is mended to full dose；
（c）By step（b）The mixed liquor for obtaining is injected in the infusion bottle, is controlled remaining oxygen control in which and, less than 2.0%, is rolled
Sterilize after lid sealing.
4. the preparation method of Amino Acid Compound Injection according to claim 3, it is characterised in that：Step（a）In, the alkali
Containing the NaOH that mass concentration is 1 ~ 2% in water, its temperature is 45 ~ 55 DEG C；The water for injection temperature is maintained at more than 70 DEG C；
Flushing pressure is not less than 0.15MPa.
5. the preparation method of Amino Acid Compound Injection according to claim 3, it is characterised in that：Step（b）In, after-teeming is penetrated
With being added thereto to account for the needle-use activated carbon that its mass fraction is 0.02 ~ 0.1% after water to full dose, its pH is stirred and controls for 6.8
~7.8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610936010.5A CN106491601A (en) | 2016-10-24 | 2016-10-24 | A kind of Amino Acid Compound Injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610936010.5A CN106491601A (en) | 2016-10-24 | 2016-10-24 | A kind of Amino Acid Compound Injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106491601A true CN106491601A (en) | 2017-03-15 |
Family
ID=58319005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610936010.5A Pending CN106491601A (en) | 2016-10-24 | 2016-10-24 | A kind of Amino Acid Compound Injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491601A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721596A (en) * | 2018-06-29 | 2018-11-02 | 复旦大学附属中山医院 | A kind of compound amino acid vitamin injection and its application |
| CN114601846A (en) * | 2020-12-03 | 2022-06-10 | 河北科星药业有限公司 | Complex vitamin amino acid injection for livestock and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940628A (en) * | 2012-10-10 | 2013-02-27 | 八峰药化宜昌有限责任公司 | Compound amino acid injection and preparation method thereof |
| CN103006643A (en) * | 2011-09-28 | 2013-04-03 | 辽宁海思科制药有限公司 | Compound injection containing 18 amino acids and preparation method thereof |
| CN103638018A (en) * | 2013-12-03 | 2014-03-19 | 辽宁海思科制药有限公司 | Compound amino acid injection 18AA-VII pharmaceutical composition and preparation method thereof |
-
2016
- 2016-10-24 CN CN201610936010.5A patent/CN106491601A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006643A (en) * | 2011-09-28 | 2013-04-03 | 辽宁海思科制药有限公司 | Compound injection containing 18 amino acids and preparation method thereof |
| CN102940628A (en) * | 2012-10-10 | 2013-02-27 | 八峰药化宜昌有限责任公司 | Compound amino acid injection and preparation method thereof |
| CN103638018A (en) * | 2013-12-03 | 2014-03-19 | 辽宁海思科制药有限公司 | Compound amino acid injection 18AA-VII pharmaceutical composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张秀清: "影响大输液澄明度因素的研究", 《实用医技杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721596A (en) * | 2018-06-29 | 2018-11-02 | 复旦大学附属中山医院 | A kind of compound amino acid vitamin injection and its application |
| CN114601846A (en) * | 2020-12-03 | 2022-06-10 | 河北科星药业有限公司 | Complex vitamin amino acid injection for livestock and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104257583B (en) | Pearl enzymolysis solution and preparation method thereof | |
| RU2008143310A (en) | METHODS OF TREATMENT WITH USE OF CITRULLIN | |
| CN102170876B (en) | Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient | |
| CN109757732A (en) | A kind of oral liquid polypeptide powder and preparation method thereof | |
| CN110548129B (en) | Compound amino acid dipeptide injection and preparation method and application thereof | |
| CN106491601A (en) | A kind of Amino Acid Compound Injection and preparation method thereof | |
| CN102600123A (en) | New application of arginine | |
| CN104042645B (en) | Compound amino acid injection | |
| JP3914585B2 (en) | Macrophage nitric oxide production enhancer | |
| CN1101377A (en) | Enzymolytic egg albumen solution as health-care liquid | |
| CN108371326B (en) | Functional composition for reducing blood sugar | |
| CN101332195B (en) | Compound branched chain amino acid injection | |
| CN102948733B (en) | Production method and formula of special-eating life nutrition liquid | |
| CN103071145B (en) | N(2)-L-alanyl-L-glutamine/compound amino acid injection (18AA-V) pharmaceutical composite preparation | |
| CN110151746A (en) | A kind of preparation method of fructosyl amino acid nutrient solution | |
| CN1264519C (en) | Notoginseng total saponin amino acid transfusion liquid and its producing method | |
| RU2721605C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
| CN109452653A (en) | Join brain peptide composition and its application | |
| CN101264316B (en) | Preparation of medicinal protolysate | |
| CN1278701C (en) | Infusion of astragalus root and amino acid and its preparing method | |
| CN1297287C (en) | Compound red sage root and amino acid infusion and its preparing method | |
| CN107455624A (en) | A kind of compound amino acid sports drink | |
| CN1297307C (en) | Infusion of gen-seng, lilyturf root and amino acid and its preparing method | |
| CN103751410A (en) | Health care wine for nourishing the liver, improving vision, tonifying essence and nourishing kidney | |
| CN1745627A (en) | Ostrich blood and active function of related products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |